Celldex Therapeutics Stock Performance

CLDX Stock  USD 23.00  0.57  2.42%   
The firm shows a Beta (market volatility) of 1.22, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celldex Therapeutics will likely underperform. At this point, Celldex Therapeutics has a negative expected return of -0.15%. Please make sure to confirm Celldex Therapeutics' downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Celldex Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Celldex Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more

Actual Historical Performance (%)

One Day Return
(2.42)
Five Day Return
(0.65)
Year To Date Return
(14.85)
Ten Year Return
(80.06)
All Time Return
(97.38)
Last Split Factor
1:15
Dividend Date
2019-02-11
Last Split Date
2019-02-11
1
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
12/09/2025
2
Disposition of 11000 shares by Ronald Pepin of Celldex Therapeutics at 2.78 subject to Rule 16b-3
12/15/2025
3
Celldex Therapeutics Shows Improved Relative Strength Still Shy Of Benchmark
12/22/2025
4
Celldex Therapeutics Scores Relative Strength Rating Upgrade Hits Key Threshold
12/31/2025
5
Acquisition by Sam Martin of 4817 shares of Celldex Therapeutics at 10.38 subject to Rule 16b-3
01/02/2026
6
Celldex Therapeutics, Inc. Stock Analysis Unpacking a 107.86 percent Potential Upside in Biotech Innovation - DirectorsTalk Interviews
01/13/2026
7
Will Celldex Therapeutics Inc. stock hit new highs in YEAR - Weekly Stock Recap Pattern Based Trade Signal System - mfd.ru
01/23/2026
8
Is Celldex Therapeutics Pricing Reflect Its DCF Upside After Mixed MultiYear Returns
01/28/2026
9
Celldex Therapeutics, Inc. Stock Analysis Exploring a Potential 116 percent Upside in Biotech Innovation - DirectorsTalk Interviews
02/03/2026
10
Celldex to Present at Upcoming Investor Conferences - marketscreener.com
02/09/2026
11
Will Celldex Therapeutics Inc. benefit from geopolitical trends - 2025 Volume Leaders High Accuracy Investment Signals - mfd.ru
02/13/2026
Begin Period Cash Flow34.8 M
Total Cashflows From Investing Activities-290.1 M
Free Cash Flow-159.7 M

Celldex Therapeutics Relative Risk vs. Return Landscape

If you would invest  2,600  in Celldex Therapeutics on November 16, 2025 and sell it today you would lose (300.00) from holding Celldex Therapeutics or give up 11.54% of portfolio value over 90 days. Celldex Therapeutics is currently does not generate positive expected returns and assumes 3.0688% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Celldex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Celldex Therapeutics is expected to under-perform the market. In addition to that, the company is 3.98 times more volatile than its market benchmark. It trades about -0.05 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of volatility.

Celldex Therapeutics Target Price Odds to finish over Current Price

The tendency of Celldex Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 23.00 90 days 23.00 
about 98.0
Based on a normal probability distribution, the odds of Celldex Therapeutics to move above the current price in 90 days from now is about 98.0 (This Celldex Therapeutics probability density function shows the probability of Celldex Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.22 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Celldex Therapeutics will likely underperform. Additionally Celldex Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Celldex Therapeutics Price Density   
       Price  

Predictive Modules for Celldex Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Celldex Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celldex Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
19.9723.0426.11
Details
Intrinsic
Valuation
LowRealHigh
20.7030.0133.08
Details
14 Analysts
Consensus
LowTargetHigh
48.5553.3659.23
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.22-1.06-0.96
Details

Celldex Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Celldex Therapeutics is not an exception. The market had few large corrections towards the Celldex Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Celldex Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Celldex Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.0094
β
Beta against Dow Jones1.22
σ
Overall volatility
1.52
Ir
Information ratio 0

Celldex Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Celldex Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Celldex Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Celldex Therapeutics generated a negative expected return over the last 90 days
Celldex Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 7.02 M. Net Loss for the year was (157.86 M) with loss before overhead, payroll, taxes, and interest of (214.08 M).
Celldex Therapeutics currently holds about 356.82 M in cash with (157.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63.
Celldex Therapeutics has a poor financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Will Celldex Therapeutics Inc. benefit from geopolitical trends - 2025 Volume Leaders High Accuracy Investment Signals - mfd.ru

Celldex Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Celldex Stock often depends not only on the future outlook of the current and potential Celldex Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Celldex Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding64.4 M
Cash And Short Term Investments725.3 M

Celldex Therapeutics Fundamentals Growth

Celldex Stock prices reflect investors' perceptions of the future prospects and financial health of Celldex Therapeutics, and Celldex Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celldex Stock performance.

About Celldex Therapeutics Performance

Evaluating Celldex Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Celldex Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Celldex Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand(101.51)(96.43)
Return On Tangible Assets(0.24)(0.25)
Return On Capital Employed(0.23)(0.24)
Return On Assets(0.18)(0.19)
Return On Equity(0.19)(0.20)

Things to note about Celldex Therapeutics performance evaluation

Checking the ongoing alerts about Celldex Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Celldex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Celldex Therapeutics generated a negative expected return over the last 90 days
Celldex Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 7.02 M. Net Loss for the year was (157.86 M) with loss before overhead, payroll, taxes, and interest of (214.08 M).
Celldex Therapeutics currently holds about 356.82 M in cash with (157.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63.
Celldex Therapeutics has a poor financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Will Celldex Therapeutics Inc. benefit from geopolitical trends - 2025 Volume Leaders High Accuracy Investment Signals - mfd.ru
Evaluating Celldex Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Celldex Therapeutics' stock performance include:
  • Analyzing Celldex Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celldex Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Celldex Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Celldex Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celldex Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Celldex Therapeutics' stock. These opinions can provide insight into Celldex Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Celldex Therapeutics' stock performance is not an exact science, and many factors can impact Celldex Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.